Gencurix supplies companion diagnostic kits to cancer center in India
In-Hyuk Park
Aug 18, 2023 (Gmt+09:00)
South Korean biotech company Gencurix Inc. on Friday said it started supplying its companion diagnostic test Droplex to a national cancer center in India.
The Tata Memorial Centre in Mumbai, a national comprehensive cancer center in India, is a government-affiliated medical facility for prevention, treatment, education and research of the disease.
Gencurix is supplying its companion diagnostic product Droplex POLE Mutation Test. A related device uses the droplet digital PCR platform to analyze the genes of endometrial cancer patients and check for mutations.
This year, India is expected to overtake China as the world's most populous country per the United Nations. With 1.4 billion people, the South Asian country is seeing a surge in endometrial cancer due to the spread of diagnostic tests and changes in eating habits.
"Using this introduction case as reference, we plan to make our test available at other major hospitals in India," a Gencurix source said. "Aside from this product, we're promoting the sale of other companion diagnostic test kits."